# Kara M Ruicci

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 9 papers | 106 citations | 6 h-index | 10 g-index |
| 11 ext. papers | 143 ext. citations | 5.8 avg, IF | 1.77 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 9 | Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. *Oral Oncology*, **2020**, 101, 104529 | 4.4 | 4 |
| 8 | TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K inhibition in head and neck squamous cell carcinoma. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 217 | 12.8 | 5 |
| 7 | Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models. *PLoS ONE*, **2020**, 15, e0239315 | 3.7 | 3 |
| 6 | Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status. *JCI Insight*, **2019**, 4, | 9.9 | 15 |
| 5 | Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition. *Molecular Oncology*, **2019**, 13, 2160-2177 | 7.9 | 13 |
| 4 | A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K inhibition in controlling tumor growth. *International Journal of Cancer*, **2019**, 145, 2100-2106 | 7.5 | 16 |
| 3 | ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. *Oral Oncology*, **2018**, 84, 95-103 | 4.4 | 19 |
| 2 | High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. *Oncotarget*, **2018**, 9, 26064-26071 | 3.3 | 11 |
| 1 | Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. *Oncotarget*, **2017**, 8, 71512-71519 | 3.3 | 18 |